NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
Clinical Trials
20 trialsNCT02866955 2020-03-09
EFESE
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT00002855 2018-10-31
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00038246 2018-10-31
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00165399 2018-06-25
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00052845 2016-07-01
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003584 2016-05-12
Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
University of New Mexico
Phase 2 Completed
NCT00151073 2015-01-22
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00151086 2015-01-22
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00183924 2014-05-22
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
University of Southern California
Phase 2 Completed
NCT00002721 2014-05-21
Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
University of New Mexico
Phase 1 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00014352 2013-01-16
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005048 2012-11-09
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NYU Langone Health
Phase 1 Completed
NCT00003084 2012-07-30
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00193271 2011-05-03
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00004105 2011-03-28
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Phase 1/2 Completed
NCT00193193 2010-08-04
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00541281 2009-10-27
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed